RNA interference (RNAi)

Wool heart
Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
skyscrapers in New York City

City lays foundation for RNAi renaissance with nearly $100M

Jun 8, 2026 4:00pm
RNA Concept 3D Render

Roche continues RNA return with $1.7B deal for Sanegene drug

Feb 2, 2026 8:35am
Aerska team

Irish biotech launches with $21M to shuttle RNAi meds to brain

Oct 1, 2025 10:34am
heart over ekg

Corsera launches with $50M for predictive AI tool, RNAi asset

Sep 2, 2025 6:30am
Bunch of wooden blocks with question marks on them

Federal mRNA vax grant cuts includes unrelated project

Aug 7, 2025 2:20pm